<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="830">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05150353</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A00881-54 Promoteur</org_study_id>
    <nct_id>NCT05150353</nct_id>
  </id_info>
  <brief_title>Detection of Amyloid Deposits in the Wrist by MRI With Mapping and High Resolution Sequences in Systemic Amyloidosis (AMYLOCARP)</brief_title>
  <acronym>AMYLOCARP</acronym>
  <official_title>Detection of Amyloid Deposits in the Wrist by MRI With Mapping and High Resolution Sequences in Systemic Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ramsay Générale de Santé</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Clinical Trial Experts Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ramsay Générale de Santé</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is based on the hypothesis that MRI could make it possible to non-invasively&#xD;
      detect these amyloid deposits at the level of the wrist using parametric sequences known as&#xD;
      T1 mapping, in the form of an extension of T1 in the wrists. areas where amyloid deposits are&#xD;
      found in the wrist.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 24, 2020</start_date>
  <completion_date type="Anticipated">April 24, 2022</completion_date>
  <primary_completion_date type="Actual">October 24, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>T1 measurement (ms) associated with each of the 5 regions of interest at the wrist</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Amyloid</condition>
  <condition>Systemic Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Patients with cardiac amyloidosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Wrist MRI</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Patients with cardiac amyloidosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patient group:&#xD;
&#xD;
          -  Woman or man over 18 years old&#xD;
&#xD;
          -  With ATTR or AL cardiac amyloidosis with or without carpal tunnel. The diagnosis of&#xD;
             amyloidosis must be proven by a positive myocardial biopsy or diphosphonate&#xD;
             scintigraphy.&#xD;
&#xD;
          -  Affiliate or beneficiarie of a social security scheme.&#xD;
&#xD;
          -  Having signed the free and informed consent.&#xD;
&#xD;
        Healthy volunteers:&#xD;
&#xD;
          -  Woman or man over 18 years old&#xD;
&#xD;
          -  Affiliate or beneficiarie of a social security scheme.&#xD;
&#xD;
          -  Having signed the free and informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patient group:&#xD;
&#xD;
          -  Patients participating in another clinical study.&#xD;
&#xD;
          -  Patients suffering from rheumatoid arthritis or other autoimmune disease (vasculitis,&#xD;
             lupus, scleroderma, etc.)&#xD;
&#xD;
          -  Patients with a medical history of wrist surgery (exclude the operated side).&#xD;
&#xD;
          -  Patients with a contraindication to performing an MRI (pacemaker, etc.)&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
&#xD;
          -  Protected patients: Adults under guardianship, curatorship or other legal protection,&#xD;
             deprived of their liberty by judicial or administrative decision.&#xD;
&#xD;
        Healthy volunteer:&#xD;
&#xD;
          -  Volunteers participating in another clinical study.&#xD;
&#xD;
          -  Volunteers suffering from rheumatoid arthritis or other autoimmune disease&#xD;
             (vasculitis, lupus, scleroderma, etc.)&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
&#xD;
          -  Volunteer with a contraindication to performing an MRI (pacemaker, etc.)&#xD;
&#xD;
          -  Protected volunteers: Adults under guardianship, guardianship or other legal&#xD;
             protection, deprived of their liberty by judicial or administrative decision.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-François Oudet</last_name>
    <phone>0683346567</phone>
    <email>jf.oudet@ecten.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Hélène Barba</last_name>
    <email>mh.barba@ecten.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Privé Paul d'Egine</name>
      <address>
        <city>Champigny-sur-Marne</city>
        <zip>94500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruxandra COSSON-STANESCU, Dr</last_name>
      <phone>0612247248</phone>
      <email>ruxandra.cosson@wanadoo.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 25, 2021</study_first_submitted>
  <study_first_submitted_qc>November 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>November 25, 2021</last_update_submitted>
  <last_update_submitted_qc>November 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Plaque, Amyloid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

